SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 389,949.40 |
| Enterprise Value ($M) | 398,108.40 |
| Book Value ($M) | 68,774.00 |
| Book Value / Share | 28.57 |
| Price / Book | 5.67 |
| NCAV ($M) | -44,944.00 |
| NCAV / Share | -18.67 |
| Price / NCAV | -8.68 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.40 |
| Return on Assets (ROA) | 0.24 |
| Return on Equity (ROE) | 0.53 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.94 |
| Current Ratio | 1.17 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 57,002.00 |
| Assets | 171,966.00 |
| Liabilities | 101,946.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Vanguard Group Inc | 9.53 | -7.07 | |
| 13G/A | State Street Corp | 5.52 | -6.64 | |
| 13G/A | BlackRock Inc. | 7.70 | -6.28 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 406,695 | 3,642,172 | 11.17 | |
| 542,114 | 3,048,525 | 17.78 | |
| 356,432 | 3,313,230 | 10.76 | |
| 705,256 | 3,310,282 | 21.31 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| EBS – Emergent BioSolutions Inc. | ELAN – Elanco Animal Health Incorporated |
| HYAC – Haymaker Acquisition Corp. 4 | LLY – Eli Lilly and Company |
| MRK – Merck & Co., Inc. |